New study tracks Real-World use of nasal stem cell spray for brain disorders
NCT ID NCT07521384
First seen May 01, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, or Parkinson's disease who are already receiving intranasal stem cells or exosomes as part of their routine care. Researchers will monitor safety and measure changes in a key inflammation marker (TNF-α) over time. The goal is to gather real-world data to guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stem Solutions
Monterrey, Nuevo León, Mexico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MuSE stem cells and MuSE cell-derived exosomes
What this could lead to
If successful, this study could provide early evidence on whether these intranasal therapies are safe and reduce inflammation, pointing toward larger trials for conditions like traumatic brain injury or Parkinson's disease.
What could go wrong
This is a small observational study (36 people) with no control group, so it cannot prove the therapy works. Results may be influenced by other treatments participants receive.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.